Published • loading... • Updated
Novo Nordisk reports Phase II data for zenagamtide in diabetes
Summary by Verdict Hospital
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novo Nordisk reports Phase II data for zenagamtide in diabetes
Novo Nordisk has reported results from its Phase II study of zenagamtide, showing drops in blood sugar and body weight among T2D adults compared to placebo.The post Novo Nordisk reports Phase II data for zenagamtide in diabetes appeared first on Hospital Management.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
